Dupilumab to induce tolerance to SLIT-Melocotón®.

Zamarro Parra, M S; Petryk Petryk, Y; San Román Sirvent, S; Navarro Garrido, C; Escudero Pastor, A; Miralles López, J C; Carbonell Martínez, A

Zamarro Parra, M S; Petryk Petryk, Y; San Román Sirvent, S; Navarro Garrido, C; Escudero Pastor, A; Miralles López, J C; Carbonell Martínez, A.

Afiliação

Zamarro Parra MS; General Universitary Hospital Reina Sofía, Murcia, Spain.
Petryk Petryk Y; General Universitary Hospital Reina Sofía, Murcia, Spain.
San Román Sirvent S; General Universitary Hospital Reina Sofía, Murcia, Spain.
Navarro Garrido C; General Universitary Hospital Reina Sofía, Murcia, Spain.
Escudero Pastor A; General Universitary Hospital Reina Sofía, Murcia, Spain.
Miralles López JC; General Universitary Hospital Reina Sofía, Murcia, Spain.
Carbonell Martínez A; General Universitary Hospital Reina Sofía, Murcia, Spain.

Eur Ann Allergy Clin Immunol ; 2023 Jan 13.

Article em En | MEDLINE | ID: mdl-36637172

Palavras-chave

LTP-syndrome; dupilumab; food allergy; induction; omalizumab; panallergen; r Prup3; sublingual immunotherapy; switch; tolerance

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Eur Ann Allergy Clin Immunol Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google